Watchlist Price Alert

Monte Rosa Therapeutics I... (GLUE)

NASDAQ: GLUE · Real-Time Price · USD

4.82

-0.09 (-1.83%)

At close: Jun 16, 2025, 3:59 PM

4.86

0.81%

Pre-market: Jun 17, 2025, 07:38 AM EDT

-1.83% (1D)

Bid	4.16
Market Cap	296.54M
Revenue (ttm)	159.49M
Net Income (ttm)	6.15M
EPS (ttm)	0.12
PE Ratio (ttm)	40.18
Forward PE	-3.41
Analyst	Buy

Ask	4.99
Volume	504,752
Avg. Volume (20D)	667,979
Open	5.01
Previous Close	4.91
Day's Range	4.66 - 4.96
52-Week Range	3.21 - 12.40
Beta	1.40

About GLUE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GLUE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

7 months ago

+93.87%

Monte Rosa Therapeutics shares are trading higher ... Unlock content with Pro Subscription

News

1 week ago · zacks.com

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 222.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

1 month ago · zacks.com

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year a...

2 months ago · seekingalpha.com

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic ...

2 months ago · zacks.com

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year a...